PHARMALEX
The computed 12-month bankruptcy probability of PHARMALEX is 0.1% (very low). The 2025 annual accounts show equity of €1.92M and a net result of €65k. Equity remains stable across the filed fiscal years (±1.7% per year). Its solvency ranks better than 95% of 147 sector peers (fiscal year 2025). The company has been active since 2000 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €1.92M |
| Net result | €65k |
| Staff (FTE) | 15 |
| Better than sector | 95% |
Strong profile, led by solvency.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 84.3% | 16.1% | |
| Net result | €65k | €113k | |
| Equity | €1.92M | €82k | |
| Gross operating margin | €1.16M | €375k | |
| Staff costs | €1.06M | €461k |
| Fiscal year | 2025 |
|---|---|
| Revenue | - |
| EBITDA | €90k |
| Net profit | €65k |
| Cash flow | €66k |
| Staff costs | €1.06M |
| Income taxes | €34k |
| Dividends | - |
| Total assets | €2.27M |
| Equity | €1.92M |
| Debt | €356k |
| of which ≤ 1y | €356k |
| of which > 1y | - |
| Working capital | €1.91M |
| Employees (FTE) | 15.0 |
| 2025 | |
|---|---|
| Current ratio | 6.37 |
| Quick ratio | 6.37 |
| Working capital ratio | 84.1% |
| Solvency | 84.3% |
| Debt / equity | 0.19 |
| Long-term debt ratio | - |
| Interest coverage | 32.24 |
| Gross margin | - |
| Net margin | - |
| ROA | 2.9% |
| ROE | 3.4% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €2.27M |
| Fixed assets | 21/28 | €6k |
| Tangible fixed assets | 22/27 | €6k |
| Current assets | 29/58 | €2.27M |
| Amounts receivable within one year | 40/41 | €1.80M |
| Cash & bank | 54/58 | €432k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €2.27M |
| Equity | 10/15 | €1.92M |
| Contributions / capital | 10/11 | €19k |
| Reserves | 13 | €1.89M |
| Accumulated profits (losses) | 14 | €7k |
| Amounts payable | 17/49 | €356k |
| Amounts payable within one year | 42/48 | €356k |
| Trade debts payable within one year | 44 | €108k |
| Income statement | ||
| Gross operating margin | 9900 | €1.16M |
| Operating result | 9901 | €88k |
| Financial income | 75 | €13k |
| Financial charges | 65 | €3k |
| Result before taxes | 9903 | €99k |
| Income taxes | 67/77 | €34k |
| Net result for the period | 9904 | €65k |
| Result to be appropriated | 9905 | €32k |
| NACE primary | Accountants(69201) |
| Legal form | Private limited company(610) |
| Incorporation | 19-05-2000 |
| Status | Active |
| Postal code | 4020 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62817B0289/00P003 | Wallonia | 405 m² | 1 · 207 m² | 8.8 m · 3 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
28-02-2023 Benjamin Gorlier appointed as statutory auditor
- Benjamin Gorlier, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Benjamin Gorlier",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": {
"kbo": null,
"name": "CDP PETIT \u0026 Co",
"address": null,
"country": null,
"legal_form": "SRL"
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "Nomme \u003C La SRL CDP PETIT \u0026 Co, ayant pour repr\u00E9sentant permanent Benjamin Gorlier en qualit\u00E9 de Commissaire de la Soci\u00E9t\u00E9 PHARMALEX.",
"decharge_status": null,
"mandate_duration": {
"kind": "until_agm_year",
"value": "2025"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": null,
"filing_date": "2022-09-22",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [
{
"body": "enig_aandeelhouder_schriftelijk",
"date": "2022-09-22",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0471.925.883",
"name_full": "PHARMALEX",
"legal_form": "SRL"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Guy BERNARD",
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"23028863"
],
"corrected_publication_numac": null
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | PHARMALEX |